North America Chlamydia Infection Diagnostics and Therapeutics Market

North America Chlamydia Infection Diagnostics & Therapeutics Market Size (2023 to 2028)

The size of the Chlamydia Infection Diagnostics and Therapeutics Market in North America was around USD 0.95 billion in 2023. It is expected to grow at a CAGR of 5.6% to reach USD 1.25 billion by 2028. It captures 40% of the global market.

The rise in the provenance of diseases such as chlamydia infection, sexually transmitted diseases, is leading to a constant increase in demand for the North America chlamydia infection diagnostics therapeutics market. High risk of contamination of chlamydia among younger people is also propelling the growth of the market. In North America, government authorities are taking initial steps to enhance healthcare services and with advanced therapeutic and diagnostic techniques which are contributing to the growth of this market. The novel devices for diagnosing infections are continuously emerging into the market owing to the intensive research, and technological developments are propelling the growth of the Chlamydia infection diagnostics and therapeutics market in North America. The availability of adequate and sensitive diagnostics tests in North America is also fuelling the growth rate of the Chlamydia infection diagnostics and therapeutics market in this region. 

Fear of shame associated with chlamydia diagnosis and therapies among younger people primarily between the age groups amid 16 and 25, due to which they might avoid screening and determination of the disease, and this is the challenging the growth of North America Chlamydia infection diagnosis and therapeutics market. 

A rising account of STDs and steadily increasing patient base are likely to boost the demand for chlamydia infection diagnostics and therapeutics which are expected to offer growth opportunities for the stakeholders in the market during the forecast period. Intensive focus on initiatives from the private and public organizations for developing innovative Chlamydia infection diagnostics and therapeutics owing to immense advancements in medical science and technology in order to meet the continuously rising demand of the medical needs is expected to be creating more growth opportunities for the regional market over the forecast period. 

This research report is segmented & sub-segmented into the following categories:

• By Product: Diagnostics (Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests and PCR), Therapeutics (Macrolides, Quinolones, Sulfonamides, Tetracycline and Aminopenicillins)
• By End User: Diagnostics (Hospitals, Specialty Clinics and Diagnostic Centers), Therapeutics (Hospital Pharmacies, Drugstores, Retail Pharmacies and Online Pharmacies
• By Country: United States, Canada and Rest of North America

Regionally, increasing prevalence of infections among younger people due to biological factors is boosting the number of opportunities for the growth of the Chlamydia infection diagnostics and therapeutics market in North America. Also, easy approval of novel devices for therapeutic procedures is anticipated to create growth opportunities for the chlamydia infection diagnosis and therapeutics market in North America. Increasing expenditure of healthcare and boosting economies of the countries like the U.S, Canada and others in North America are foreseen to create lucrative opportunities for the market players in the region during the projection period.

Key players in the North America Chlamydia Infection Diagnostics & Therapeutics Market include Bio Rad laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.